beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
about
Alzheimer mechanisms and therapeutic strategies11 C-PIB-PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's diseaseMisfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathiesSystematic mutagenesis of α-synuclein reveals distinct sequence requirements for physiological and pathological activitiesCerebrospinal Fluid Amyloid β1-42, Tau, and Alpha-Synuclein Predict the Heterogeneous Progression of Cognitive Dysfunction in Parkinson's DiseaseDisease-modifying therapeutic directions for Lewy-Body dementiasAlzheimer's in 3D culture: challenges and perspectivesAssessing the causes and consequences of co-polymerization in amyloid formationNeuropathological alterations in Alzheimer diseaseCross-seeding of misfolded proteins: implications for etiology and pathogenesis of protein misfolding diseasesParkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies.Three dimensions of the amyloid hypothesis: time, space and 'wingmen'What is the Clinical Significance of Cerebrospinal Fluid Biomarkers in Parkinson's disease? Is the Significance Diagnostic or Prognostic?Association of the cytoskeletal GTP-binding protein Sept4/H5 with cytoplasmic inclusions found in Parkinson's disease and other synucleinopathiesBeta-amyloid deposition in chronic traumatic encephalopathyPeptides of presenilin-1 bind the amyloid precursor protein ectodomain and offer a novel and specific therapeutic approach to reduce ß-amyloid in Alzheimer's diseaseAmyloid is linked to cognitive decline in patients with Parkinson disease without dementiaPassive immunization reduces behavioral and neuropathological deficits in an alpha-synuclein transgenic model of Lewy body diseaseOrganically modified silica nanoparticles: a nonviral vector for in vivo gene delivery and expression in the brain.Gamma-synucleinopathy: neurodegeneration associated with overexpression of the mouse protein.A β-synuclein mutation linked to dementia produces neurodegeneration when expressed in mouse brainAlzheimer disease models and human neuropathology: similarities and differencesQuantitative changes in calretinin immunostaining in the cochlear nuclei after unilateral cochlear removal in young ferretsNext-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.Molecular imaging biomarkers for dementia with Lewy bodies: an update.Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases.Long-term neprilysin gene transfer is associated with reduced levels of intracellular Abeta and behavioral improvement in APP transgenic miceModulation of alpha-synuclein expression in transgenic animals for modelling synucleinopathies--is the juice worth the squeeze?In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementiaEpilepsy and cognitive impairments in Alzheimer diseaseAssociation of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathyCombined immunotherapy with "anti-insulin resistance" therapy as a novel therapeutic strategy against neurodegenerative diseases.Evaluation of plant phenolic metabolites as a source of Alzheimer's drug leads.Multiple pathogenic proteins implicated in neuronopathic Gaucher disease miceReducing C-terminal-truncated alpha-synuclein by immunotherapy attenuates neurodegeneration and propagation in Parkinson's disease-like models.Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study.Familial associations of Alzheimer disease and essential tremor with Parkinson disease.Alzheimer disease with amygdala Lewy bodies: a distinct form of alpha-synucleinopathy.
P2860
Q22252311-F5F47022-8DA6-4346-B28D-0A21C85F59D8Q24194742-7A9BC621-3EEC-49E1-B42B-D4B4E1617547Q24318974-245D5BA9-BD92-4F44-A81E-06F3BBA65A64Q24554351-EA424979-92B0-4362-A5C7-428E054D60DAQ26269871-A75561BC-FF6D-4841-A963-11328C8454A7Q26744782-BFEB47A7-830E-4B57-9839-50E2D87011FAQ26782907-08092F4A-C2A6-4A5D-B98E-8D70E942E91EQ26801081-20232D18-3D13-40B8-B016-54FFF39DE532Q26824195-E9BFEC01-2023-468C-9B1F-FD8847230563Q27003314-6346E60C-28D2-41BE-B51C-A4495A3BFEA7Q27021846-46ECC9BA-4CE0-45C8-A216-C511D6495C00Q27686837-1A94F05E-7AC8-47C9-BE22-FC35F23C51BFQ28082768-D39E2BEC-9D4B-4D85-8751-E80F96774FE4Q28083203-6FB7A082-FB11-4089-8723-AE9828D0224CQ28191071-CE4C2424-13AB-4D70-AEC9-B58580F2E141Q28385330-15457CAA-E080-4D3D-A69B-33A6C0160618Q28546835-5F82AA55-150A-4AD3-AA7D-4DA310A148B5Q28705235-CEB613AC-D8E9-4FB4-92F7-E0D985B06285Q28740551-DCBA3CF6-5810-4A98-839F-611D6F4D30ECQ30476054-F3CA8860-6E6C-4C0D-9D2D-E8F007FDF5FFQ30487162-FC95C75C-A623-4567-A49D-D32BF11C8B97Q30498862-32FEFF2E-A416-453A-9541-BCAD97C8B519Q30499574-15FF62C8-1EF9-437F-871D-6870730A5709Q30502951-45C2E07D-1E82-4D45-B6F7-1CE4DC89108EQ30578913-6514C736-0897-4CB1-BEEF-E8409189E092Q30881333-AF362B7D-234A-48B8-9CFF-7AF26F5BE6B1Q33366459-850C2434-0A23-4D77-B9E8-231CBD739316Q33384861-DF1BEEEE-385A-41ED-B685-5F709666AF51Q33392127-B4344671-EE72-4044-A217-E0D8854D1370Q33601277-3129FA92-4383-4F4C-8C07-A9187464B76CQ33616746-47D77CA5-BDC6-4B74-9B18-F5DF89F049F5Q33666297-A55A7389-982C-4C53-B4B7-CDCA8A2FA064Q33670282-8C5C429D-7567-4972-BE5A-7A9089F77C93Q33731321-73817622-1EDB-4B50-BF0D-4EBD8B292396Q33791575-6D02734B-25AC-4C6E-8C7B-76962A894770Q33847578-15B56E69-1F91-4272-87AB-770BB86C4EA8Q33865366-A77A0B78-42C8-44EF-82AE-CD984F83D90EQ33917300-46297FCF-722A-4BDA-9C35-DE6DC1992812Q33955534-91D9F97A-71F1-4CBE-BB46-3259342001CFQ33997481-24B3DF9B-7DBF-4EA4-95C8-EAECF8594CDE
P2860
beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
beta-amyloid peptides enhance ...... sease and Parkinson's disease.
@ast
beta-amyloid peptides enhance ...... sease and Parkinson's disease.
@en
type
label
beta-amyloid peptides enhance ...... sease and Parkinson's disease.
@ast
beta-amyloid peptides enhance ...... sease and Parkinson's disease.
@en
prefLabel
beta-amyloid peptides enhance ...... sease and Parkinson's disease.
@ast
beta-amyloid peptides enhance ...... sease and Parkinson's disease.
@en
P2093
P2860
P921
P356
P1476
beta-amyloid peptides enhance ...... sease and Parkinson's disease.
@en
P2093
E Rockenstein
I Veinbergs
M Hashimoto
P2860
P304
12245-12250
P356
10.1073/PNAS.211412398
P407
P577
2001-09-25T00:00:00Z